Table 3 |
||||
|
Discontinuation rates at 1 year for anti-TNF agents in randomized clinical trials |
||||
|
Trial |
No. of patients |
Patient characteristics |
Regimens |
Discontinuation rates (%) |
|
|
||||
|
ATTRACT [12] |
428 |
Active RA despite methotrexate therapy; mean duration 9–12 years |
Infliximaba |
21 |
|
3 mg q 4 weeks |
||||
|
3 mg q 8 weeks |
||||
|
10 mg q 4 weeks |
||||
|
10 mg q 8 weeks |
||||
|
Placeboa (weekly) |
50 |
|||
|
ERA [14] |
632 |
Early RA; mean duration <1 year (i.e. 11–12 months) |
Etanercept |
|
|
25 mg twice weekly |
15 |
|||
|
Methotrexate (mean, 19 mg) weekly |
21 |
|||
|
|
||||
|
aAll groups also received methotrexate, mean 16–17 mg/week. ATTRACT, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy; ERA, Early Rheumatoid Arthritis. |
||||
|
Yocum Arthritis Res Ther 2004 6(Suppl 2):S24 doi:10.1186/ar997 |
||||